Humedics GmbH
Humedics GmbH is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Humedics GmbH.
Humedics GmbH is a company.
Key people at Humedics GmbH.
Key people at Humedics GmbH.
Humedics GmbH is a Berlin-based medtech company founded in 2009 that develops and commercializes the LiMAx® test, an innovative breath analysis technology for rapid, precise, non-invasive measurement of liver function capacity at the bedside.[1][2][6] The product serves physicians in hepatology, liver surgery, transplantation, and oncology by quantifying individual liver function in minutes via exhaled air analysis, enabling better treatment decisions, surgical planning, and monitoring of diseases like fibrosis, cirrhosis, and post-transplant recovery.[1][2][5][6] With around 10 employees and $5.2 million in revenue, Humedics has tested LiMAx on thousands of patients, published in top journals, and is scaling production while expanding globally, backed by early investors like High-Tech Gründerfonds.[1][2]
Humedics emerged as a spin-off from Freie Universität Berlin and Charité university hospital, founded in 2009 by Karsten Heyne, a professor specializing in ultrafast spectroscopy for biological systems, and Martin Stockmann, a chief physician leading liver surgery and transplantation research with over 100 publications.[2][3] The idea stemmed from their work developing the LiMAx prototype for instantaneous bedside liver function testing, initially funded by High-Tech Gründerfonds.[2][3] Key milestones include a 2011 funding round with investors like Charité Biomedical Fonds, KfW, VC Fonds Technologie Berlin, and Ventegis Capital, plus a major 2014 innovation award, marking early traction and production scale-up.[2]
Humedics rides the wave of precision diagnostics and personalized medicine in medtech, where non-invasive, real-time tests address rising liver disease burdens from NAFLD, alcohol-related issues, and oncology, amid demands for individualized therapies.[1][3][6] Timing aligns with aging populations and post-COVID hepatology needs, plus regulatory pushes for functional over structural diagnostics; market forces favor breath-based biomarkers for cost-effective, scalable alternatives to imaging/biopsies.[1][2] By enabling safer surgeries and transplants, Humedics influences the ecosystem, contributing to over 20 new indication studies and integrating into hospital workflows globally.[1][2]
Humedics is poised for accelerated growth through LiMAx commercialization, likely via partnerships, regulatory approvals in new markets, and expanded indications from ongoing trials.[1][2] Trends like AI-enhanced diagnostics and rising liver cancer/transplant volumes will propel demand, potentially boosting revenue beyond $5M as production scales.[1] Its influence may evolve from niche innovator to standard in functional liver assessment, tying back to its origins in revolutionizing bedside certainty for patient safety.[6]
